Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.
Xiamen Amoytop Biotech Co Ltd (688278) - Net Assets
Latest net assets as of June 2025: CN¥2.76 Billion CNY
Based on the latest financial reports, Xiamen Amoytop Biotech Co Ltd (688278) has net assets worth CN¥2.76 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.21 Billion) and total liabilities (CN¥453.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.76 Billion |
| % of Total Assets | 85.85% |
| Annual Growth Rate | 23.3% |
| 5-Year Change | 155.23% |
| 10-Year Change | N/A |
| Growth Volatility | 23.0 |
Xiamen Amoytop Biotech Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Xiamen Amoytop Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xiamen Amoytop Biotech Co Ltd (2016–2024)
The table below shows the annual net assets of Xiamen Amoytop Biotech Co Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.55 Billion | +36.08% |
| 2023-12-31 | CN¥1.88 Billion | +33.30% |
| 2022-12-31 | CN¥1.41 Billion | +21.21% |
| 2021-12-31 | CN¥1.16 Billion | +16.08% |
| 2020-12-31 | CN¥1.00 Billion | +77.52% |
| 2019-12-31 | CN¥563.55 Million | +12.88% |
| 2018-12-31 | CN¥499.26 Million | +3.31% |
| 2017-12-31 | CN¥483.26 Million | +1.08% |
| 2016-12-31 | CN¥478.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xiamen Amoytop Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 32919.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.55 Billion | 60.72% |
| Other Components | CN¥1.00 Billion | 39.28% |
| Total Equity | CN¥2.55 Billion | 100.00% |
Xiamen Amoytop Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Xiamen Amoytop Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
$1.64 Billion |
|
Songcheng Performance Develop
SHE:300144
|
$1.64 Billion |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
$1.64 Billion |
|
Forvia SE
PA:FRVIA
|
$1.64 Billion |
|
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
|
$1.63 Billion |
|
Guizhou Chanhen Chemical Corp
SHE:002895
|
$1.63 Billion |
|
CompoSecure, Inc.
NYSE:CMPO
|
$1.63 Billion |
|
Inner Mongolia First Machinery Group Co Ltd
SHG:600967
|
$1.63 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xiamen Amoytop Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,876,401,343 to 2,553,316,292, a change of 676,914,949 (36.1%).
- Net income of 827,602,234 contributed positively to equity growth.
- Dividend payments of 166,788,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥827.60 Million | +32.41% |
| Dividends Paid | CN¥166.79 Million | -6.53% |
| Other Changes | CN¥16.10 Million | +0.63% |
| Total Change | CN¥- | 36.08% |
Book Value vs Market Value Analysis
This analysis compares Xiamen Amoytop Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 52.78x to 11.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.34 | CN¥70.79 | x |
| 2018-12-31 | CN¥1.39 | CN¥70.79 | x |
| 2019-12-31 | CN¥1.56 | CN¥70.79 | x |
| 2020-12-31 | CN¥2.46 | CN¥70.79 | x |
| 2021-12-31 | CN¥2.85 | CN¥70.79 | x |
| 2022-12-31 | CN¥3.46 | CN¥70.79 | x |
| 2023-12-31 | CN¥4.61 | CN¥70.79 | x |
| 2024-12-31 | CN¥6.28 | CN¥70.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xiamen Amoytop Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 32.41%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.38%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 1.19x
- Recent ROE (32.41%) is above the historical average (14.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 6.13% | 10.46% | 0.44x | 1.34x | CN¥-18.49 Million |
| 2017 | 1.07% | 1.60% | 0.51x | 1.32x | CN¥-43.16 Million |
| 2018 | 3.21% | 3.57% | 0.63x | 1.42x | CN¥-33.92 Million |
| 2019 | 11.41% | 8.81% | 0.92x | 1.40x | CN¥7.94 Million |
| 2020 | 11.65% | 14.68% | 0.67x | 1.19x | CN¥16.53 Million |
| 2021 | 15.60% | 16.00% | 0.80x | 1.23x | CN¥65.07 Million |
| 2022 | 20.39% | 18.80% | 0.86x | 1.26x | CN¥146.26 Million |
| 2023 | 29.60% | 26.45% | 0.89x | 1.26x | CN¥367.81 Million |
| 2024 | 32.41% | 29.38% | 0.92x | 1.19x | CN¥572.27 Million |
Industry Comparison
This section compares Xiamen Amoytop Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,722,009,584
- Average return on equity (ROE) among peers: 7.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xiamen Amoytop Biotech Co Ltd (688278) | CN¥2.76 Billion | 6.13% | 0.16x | $1.64 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $183.33 Million | -11.06% | 0.92x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.03 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $248.75 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $860.44 Million |
| Hualan Biological EngineeringInc (002007) | $4.84 Billion | 16.95% | 0.08x | $2.01 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.20 Billion | 4.62% | 0.66x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.81 Billion | 11.12% | 0.67x | $414.37 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.77 Billion | 15.42% | 0.67x | $347.52 Million |